Payment overview · 2025
General Payments
$744.01
40 reported records · 13 companies
Healthcare provider profile · identity verified
William Bader, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CARNEGIE, PA · NPI 1871563411
Verified facts
What the public records show
CMS Open Payments records show William Bader, M.D. received $744.01 in general payments during 2025 across 40 reported records.
Lilly USA, LLC accounted for 28.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $213.05 | 28.6% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $98.25 | 13.2% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $74.83 | 10.1% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $67.85 | 9.1% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $62.39 | 8.4% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $61.23 | 8.2% | 3 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $60.71 | 8.2% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $24.83 | 3.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.61 | 2.5% | 1 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $16.45 | 2.2% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $16.30 | 2.2% | 1 | 2025 |
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $14.80 | 2.0% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $14.71 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $699.01 | 39 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $128.48 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $128.48 | 8 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $78.77 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $74.83 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $62.39 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $61.75 | 4 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $61.23 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $60.71 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $53.06 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $53.06 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $39.57 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $24.83 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $19.48 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $19.48 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.61 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.74 | 1 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $16.45 | 1 | 2025 |
Source payment records
|
|||||
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $14.80 | 1 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $14.80 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $14.80 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $14.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 119 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 57 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
57 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
119 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 473 | 116 |
| Levothyroxine Sodium | Levothyroxine Sodium | 316 | 69 |
| Lisinopril | Lisinopril | 300 | 82 |
| Gabapentin | Gabapentin | 246 | 41 |
| Amlodipine Besylate | Amlodipine Besylate | 218 | 56 |
| Metformin Hcl | Metformin Hcl | 192 | 48 |
| Simvastatin | Simvastatin | 176 | 47 |
| Indapamide | Indapamide | 151 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 141 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 140 | 42 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 131 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 131 | 29 |
| Losartan Potassium | Losartan Potassium | 130 | 34 |
| Eliquis | Apixaban | 119 | 23 |
| Furosemide | Furosemide | 117 | 33 |
| Carvedilol | Carvedilol | 115 | 29 |
| Omeprazole | Omeprazole | 111 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 109 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 108 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 104 | 31 |
| Atenolol | Atenolol | 103 | 26 |
| Lorazepam | Lorazepam | 102 | 26 |
| Glimepiride | Glimepiride | 94 | 23 |
| Meloxicam | Meloxicam | 92 | 32 |
| Sertraline Hcl | Sertraline Hcl | 91 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 90 | 23 |
| Oxycodone Hcl | Oxycodone Hcl | 86 | 14 |
| Alendronate Sodium | Alendronate Sodium | 72 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 72 | 18 |
| Irbesartan | Irbesartan | 70 | 19 |
| Trazodone Hcl | Trazodone Hcl | 68 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 65 | suppressed |
| Famotidine | Famotidine | 64 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 11 |
| Celecoxib | Celecoxib | 60 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 58 | suppressed |
| Ibuprofen | Ibuprofen | 57 | 16 |
| Ozempic | Semaglutide | 57 | 13 |
| Spironolactone | Spironolactone | 56 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 49 | 13 |
| Alprazolam | Alprazolam | 47 | suppressed |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Mounjaro | Tirzepatide | 42 | suppressed |
| Allopurinol | Allopurinol | 41 | 12 |
| Azithromycin | Azithromycin | 41 | 30 |
| Donepezil Hcl | Donepezil Hcl | 40 | suppressed |
| Glipizide | Glipizide | 40 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | suppressed |
| Mirtazapine | Mirtazapine | 39 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 38 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 30 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 34 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 34 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 33 | 13 |
| Potassium Chloride | Potassium Chloride | 33 | suppressed |
| Ezetimibe | Ezetimibe | 32 | 11 |
| Tramadol Hcl | Tramadol Hcl | 32 | suppressed |
| Cephalexin | Cephalexin | 30 | 20 |
| Nebivolol Hcl | Nebivolol Hcl | 30 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 29 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 29 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 28 | suppressed |
| Jardiance | Empagliflozin | 28 | suppressed |
| Prednisone | Prednisone | 28 | 17 |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 19 |
| Finasteride | Finasteride | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Fentanyl | Fentanyl | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Fluocinonide | Fluocinonide | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | 11 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Adapalene | Adapalene | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $744.01 · 40 records | Lilly USA, LLC | AIRSUPRA, CHARTIS CATHETER, Cologuard Collection Kit, ELIQUIS, EVENITY, Fibroscan, JARDIANCE, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, PROLIA, PULMONX CHARTIS TABLET CONSOLE, REPATHA, Rybelsus, WATCHMAN Access System, ZEPBOUND, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error